论文部分内容阅读
目的探究依达拉奉联合阿托伐他汀治疗心源性脑栓塞患者的疗效及对T淋巴细胞亚群的影响。方法选取2014年6月~2016年6月我院94心源性脑栓塞患者,随机分组,各47例。两组均给予常规治疗,在此基础上对照组给予依达拉奉治疗,观察组采用依达拉奉+阿托伐他汀治疗,均治疗2周。对比两组治疗前后T淋巴细胞亚群(CD8+、CD4+)、活性氧簇(ROS)、谷胱甘肽过氧化物酶(GSH-Px)水平变化情况及治疗后总有效率。结果经治疗观察组CD4+、GSH-Px水平明显高于对照组,CD8+、ROS水平明显低于对照组,差异均具有统计学意义(P<0.05);治疗后观察组治疗总有效率(87.2%)优于对照组(68.1%),差异具有统计学意义(P<0.05)。结论采用依达拉奉联合阿托伐他汀治疗心源性脑栓塞疗效显著,可有效纠正T淋巴细胞失衡状态。
Objective To investigate the efficacy of edaravone plus atorvastatin in patients with cardiogenic cerebral embolism and its effect on T lymphocyte subsets. Methods From June 2014 to June 2016, 94 patients with cardiogenic brain embolism in our hospital were randomly divided into two groups, 47 cases in each group. Both groups were given conventional treatment. On the basis of this, the control group was treated with edaravone. The observation group was treated with edaravone and atorvastatin for 2 weeks. The changes of T lymphocyte subsets (CD8 +, CD4 +), reactive oxygen species (ROS) and glutathione peroxidase (GSH-Px) before and after treatment were compared between the two groups and the total effective rate after treatment. Results The levels of CD4 + and GSH-Px in the treated group were significantly higher than those in the control group, while the levels of CD8 + and ROS in the treated group were significantly lower than those in the control group (P <0.05). After treatment, the total effective rate in the observation group was 87.2% ) Than the control group (68.1%), the difference was statistically significant (P <0.05). Conclusion Edaravone combined with atorvastatin has a significant effect on cardioembolic cerebral embolism, which can effectively correct the imbalance of T lymphocytes.